| Rates of resistance to ceftazidime-avibactam and ceftolozane-tazobactam among patients treated for multidrug-resistant Pseudomonas aeruginosa bacteremia or … S Shah, EG Kline, G Haidar, KM Squires, JM Pogue, EK McCreary, ... Clinical Infectious Diseases, ciae332, 2024 | | 2024 |
| Piperacillin/tazobactam Susceptibility Test Interpretive Criteria for Enterobacterales: Recommendations from the United States Committee on Antimicrobial Susceptibility Testing TP Lodise, SM Bhavnani, PG Ambrose, HS Sader, DR Andes, JM Pogue Clinical Infectious Diseases, ciae328, 2024 | 1 | 2024 |
| Population pharmacokinetic/pharmacodynamic target attainment analysis of IV fosfomycin for the treatment of MDR Gram-negative bacterial infections W Wangchinda, JM Pogue, V Thamlikitkul, P Leelawattanachai, ... Journal of Antimicrobial Chemotherapy 79 (6), 1372-1379, 2024 | | 2024 |
| A comparison of strategies for identifying patients at risk for carbapenem-resistant or extended β-lactam-resistant Pseudomonas aeruginosa W Wangchinda, KS Kaye, TS Patel, OR Albin, L Saravolatz, JG Petrie, ... Journal of Antimicrobial Chemotherapy 79 (6), 1337-1345, 2024 | | 2024 |
| Is it time to join the oral antibiotics bandwagon? JA Justo, JM Pogue The Lancet Infectious Diseases 24 (5), 445-447, 2024 | | 2024 |
| The growing threat of NDM-producing E. coli with penicillin-binding protein 3 mutations in the United States – is there a potential role for durlobactam? SL Aitken, VM Pierce, JM Pogue, EG Kline, FP Tverdek, RK Shields Clinical Infectious Diseases, ciae229, 2024 | | 2024 |
| An Open-Label, Randomized Trial Comparing Fidaxomicin With Oral Vancomycin for the Treatment of Clostridioides difficile Infection in Hospitalized Patients … K Rao, Q Zhao, J Bell, J Krishnan, O Henig, J Daniel, K Sawaya, O Albin, ... Clinical Infectious Diseases 78 (2), 277-282, 2024 | 1 | 2024 |
| Tebipenem and Sulopenem: Dynamic Duo or Double Trouble? BR Mangum, JM Pogue, KE Barber Current Infectious Disease Reports, 1-12, 2024 | | 2024 |
| Which trial do we need? Combination antimicrobial therapy for hospital-acquired bacterial pneumonia caused by Pseudomonas aeruginosa OR Albin, JM Pogue, RG Wunderink, KS Kaye Clinical Microbiology and Infection 30 (2), 162-164, 2024 | 2 | 2024 |
| Nut cracked? Does the ACORN trial end the debate surrounding vancomycin and piperacillin-tazobactam combination therapy and increased risk for acute kidney injury? JM Pogue, SL Aitken Open Forum Infectious Diseases 11 (1), ofad645, 2024 | | 2024 |
| Impact of reducing time-to-antibiotics on sepsis mortality, antibiotic use, and adverse events JP Donnelly, SM Seelye, P Kipnis, BM McGrath, TJ Iwashyna, J Pogue, ... Annals of the American Thoracic Society 21 (1), 94-101, 2024 | 4 | 2024 |
| 1764. Collaboration between Public Health and Healthcare Partners to Attack the Rising Menace of Candida auris: The Michigan Experience BM Brennan, SE McNamara, E Stier, A Malani, JM Pogue, AM Ressler, ... Open Forum Infectious Diseases 10 (Supplement_2), ofad500. 1595, 2023 | | 2023 |
| 722. Risk Factors for Infection or Colonization with Ceftolozane/Tazobactam Non-Susceptible Extensively β-Lactam Resistant Pseudomonas aeruginosa M Lee, J Nagel, W Wangchinda, VM Pierce, A Smith, O Bishop, JM Pogue Open Forum Infectious Diseases 10 (Supplement_2), ofad500. 783, 2023 | | 2023 |
| 2186. Treatment-emergent resistance to ceftazidime-avibactam (CZA) is more common than ceftolozane-tazobactam (CT) among patients infected with multidrug-resistant (MDR … S Shah, G Haidar, KM Squires, EG Kline, JM Pogue, EK McCreary, ... Open Forum Infectious Diseases 10 (Supplement_2), ofad500. 1808, 2023 | | 2023 |
| Executive Summary: State-of-the-Art Review: State of the Management of Infections Caused by Multidrug-Resistant Gram-Negative Organisms A Yassin, M Huralska, JM Pogue, D Dixit, RG Sawyer, KS Kaye Clinical Infectious Diseases 77 (9), 1223-1225, 2023 | 1 | 2023 |
| State of the management of infections caused by multidrug-resistant Gram-negative organisms A Yassin, M Huralska, JM Pogue, D Dixit, RG Sawyer, KS Kaye Clinical Infectious Diseases 77 (9), e46-e56, 2023 | 2 | 2023 |
| What is the place in therapy for nirmatrelvir/ritonavir? TC Lee, JM Pogue, EK McCreary, AM Morris BMJ Evidence-Based Medicine 28 (5), 287-290, 2023 | 2 | 2023 |
| A population pharmacokinetic model of polymyxin B based on prospective clinical data to inform dosing in hospitalized patients PO Hanafin, A Kwa, AP Zavascki, AM Sandri, MH Scheetz, CJ Kubin, ... Clinical Microbiology and Infection 29 (9), 1174-1181, 2023 | 6 | 2023 |
| Sulbactam for Treatment of Carbapenem-Resistant Acinetobacter baumannii W Wangchinda, J Pogue MJH Life Sciences, 2023 | | 2023 |
| Case Commentary: When Voldemort Meets Sauron: Treatment Considerations for Emerging Dual-Carbapenemase-Producing Extensively Drug-Resistant Pseudomonas aeruginosa W Wangchinda, JM Pogue Antimicrobial Agents and Chemotherapy 67 (7), e00475-23, 2023 | 1 | 2023 |
